Product Description
AMT-190 is a one-time, intravenously-administered, AAV5-based gene therapy designed to circumvent GLA antibodies that can inhibit efficacy in Fabry patients. (Sourced from: https://www.sec.gov/Archives/edgar/data/1590560/000110465918069198/a18-40440_1ex99d1.htm)
Mechanisms of Action: Gene Therapy,GLA
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: UniQure N.V.
Company Location: AMSTERDAM P7 1105 BP
Company CEO: Matthew Kapusta
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Fabry Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|